Amyloid-beta peptide E22W mutant epitope-HLA complex (Aβ-E22W-HLA)

The Amyloid-beta (Aβ) peptide E22W mutant epitope-HLA complex is a specialized therapeutic target designed for precision immunotherapy in Alzheimer's disease. The E22W mutation involves a substitution of glutamic acid with tryptophan at position 22 of the Aβ peptide, a change that significantly enhances the peptide's propensity to form neurotoxic aggregates and amyloid plaques (Kourie et al., 2001). This mutant peptide is processed by cellular machinery and presented on the cell surface via Human Leukocyte Antigen (HLA) molecules, creating a unique neoantigenic signature not found in healthy individuals. Therapeutic strategies, such as TCR-engineered T-cells (TCR-T) or neoantigen vaccines, aim to recognize this specific complex to induce a targeted immune response (Parvathaneni et al., 2023). By focusing on the E22W mutant, these therapies seek to clear pathological amyloid species while sparing the physiological wild-type Aβ protein, thereby potentially reducing the risk of autoimmune-like neuroinflammation seen in earlier Aβ vaccines. This target represents a frontier in combining oncology-inspired TCR-based platforms with neurodegenerative disease treatment.

Other names

Aβ E22W neoepitopeAmyloid-beta E22W peptide-MHC complexE22W-mutated Aβ42 epitopeAβ E22W-HLA-A*02:01 complex

Engineered T-cell receptors (TCRs) or TCR-like antibodies specifically bind to the E22W-mutated Amyloid-beta peptide when it is presented by HLA molecules on the cell surface. This binding event triggers T-cell activation, leading to the release of cytotoxic granules and cytokines, which facilitates the clearance of cells producing the mutant protein or the phagocytosis of associated amyloid aggregates.